Article
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
Antimicrobial agents and chemotherapy - 1 Aug 2011
Marsden Matthew D, Avancena Patricia, Kitchen Christina M R, Hubbard Trish, Zack Jerome A
Abstract excerpt
CD4(+) T cells and macrophages are the primary target cells for HIV in vivo, and antiretroviral drugs can vary in their ability to inhibit the infection of these different cell types. Resistance pathways to the HIV integrase inhibitor raltegravir have previously been investigated in T cells. Primary raltegravir resistance mutations, most often at integrase amino acid position 148 or 155, afford some resistance to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.